FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3012096588> ?p ?o ?g. }

• W3012096588 abstract "2065 Background: Copper chelation reduces the secretion of many angiogenic factors and reduces tumour growth and microvascular density in animal models. ATN-224 is a second generation analogue of ammonium tetrathiomolybdate, which reportedly can stabilise disease but was limited by the slow onset of copper depletion (50–60 days). Preclinical studies suggest ATN-224 may act primarily by superoxide dismutase 1 (SOD-1) inhibition. The aim of our phase I study was to reduce serum copper levels, as measured by ceruloplasmin (Cp), to 5–15 mg/dl (normal 16–60) in 14–21 days, to determine the pharmacokinetic profile, and to evaluate dose-limiting toxicities. Methods: Cohorts of pts were treated with escalating doses of ATN-224, twice daily, until copper depletion, followed by a titrated maintenance dose. Serum Cp was used as a surrogate marker of copper levels and was titrated to a target range of 5–15mg/dL (normal 16–60). Results: 18 pts have received 54 cycles of ATN-224. Tumours were breast (4), renal (2), melanoma (2), colon (2), and a variety of other types (1 each). Pts received ATN 224 loading doses in cohorts of 1 to 6 pts: 150 (1), 210 (2), 240 (1), 270 (6), 300 (5), and 330 mg/day (3). Mean age was 56 yrs (range 37–78) and PS 0–2. Mean baseline Cp was 39.6 (range 22–63 mg/dL). The maximum administered dose was 330 mg/day where grade 3 lethargy was observed in 3 pts. Of the 4 pts at the maximum tolerated dose of 300 mg/day who have currently completed the loading schedule, all 4 have achieved a reduction of Cp to within 10% of the target range within 21 days. Other toxicities at this dose level included sulphur burps (Gr 1), vomiting (Gr 2), neutropenia (Gr 2), and anaemia (Gr 3). Toxicities reduced in the second and subsequent cycles when doses were titrated downward to maintain Cp levels in target range. PK data indicate greater absorption of ATN 224 and more rapid reduction in Cp with concurrent administration of a proton pump inhibitor. Stable disease of >6 months was observed in 4 pts. Conclusions: Oral ATN-224 is a well-tolerated therapy and at a loading dose of 300 mg/day leads to a reduction of serum Cp levels to 20% normal within 21 days. This will be the recommended starting dose level for phase II study. (Sponsored by Cancer Research UK; funded by Attenuon, LLC). [Table: see text]" @default.
• W3012096588 created "2020-03-23" @default.
• W3012096588 creator A5004296895 @default.
• W3012096588 creator A5013560919 @default.
• W3012096588 creator A5018411240 @default.
• W3012096588 creator A5051430596 @default.
• W3012096588 creator A5063334369 @default.
• W3012096588 creator A5065530824 @default.
• W3012096588 creator A5070885356 @default.
• W3012096588 creator A5083254857 @default.
• W3012096588 date "2006-06-20" @default.
• W3012096588 modified "2023-09-25" @default.
• W3012096588 title "Phase I study of ATN-224 in patients (pts) with advanced solid tumours" @default.
• W3012096588 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.2065" @default.
• W3012096588 hasPublicationYear "2006" @default.
• W3012096588 type Work @default.
• W3012096588 sameAs 3012096588 @default.
• W3012096588 citedByCount "0" @default.
• W3012096588 crossrefType "journal-article" @default.
• W3012096588 hasAuthorship W3012096588A5004296895 @default.
• W3012096588 hasAuthorship W3012096588A5013560919 @default.
• W3012096588 hasAuthorship W3012096588A5018411240 @default.
• W3012096588 hasAuthorship W3012096588A5051430596 @default.
• W3012096588 hasAuthorship W3012096588A5063334369 @default.
• W3012096588 hasAuthorship W3012096588A5065530824 @default.
• W3012096588 hasAuthorship W3012096588A5070885356 @default.
• W3012096588 hasAuthorship W3012096588A5083254857 @default.
• W3012096588 hasConcept C126322002 @default.
• W3012096588 hasConcept C143998085 @default.
• W3012096588 hasConcept C71924100 @default.
• W3012096588 hasConceptScore W3012096588C126322002 @default.
• W3012096588 hasConceptScore W3012096588C143998085 @default.
• W3012096588 hasConceptScore W3012096588C71924100 @default.
• W3012096588 hasLocation W30120965881 @default.
• W3012096588 hasOpenAccess W3012096588 @default.
• W3012096588 hasPrimaryLocation W30120965881 @default.
• W3012096588 hasRelatedWork W1570030451 @default.
• W3012096588 hasRelatedWork W1996702989 @default.
• W3012096588 hasRelatedWork W1999406529 @default.
• W3012096588 hasRelatedWork W2027337507 @default.
• W3012096588 hasRelatedWork W2087240036 @default.
• W3012096588 hasRelatedWork W2164797109 @default.
• W3012096588 hasRelatedWork W2169611781 @default.
• W3012096588 hasRelatedWork W2285479586 @default.
• W3012096588 hasRelatedWork W2598161334 @default.
• W3012096588 hasRelatedWork W2789708638 @default.
• W3012096588 isParatext "false" @default.
• W3012096588 isRetracted "false" @default.
• W3012096588 magId "3012096588" @default.
• W3012096588 workType "article" @default.